Enlivex Therapeutics receives a Nasdaq delisting notice and announces a 1-for-16 reverse stock split.

Enlivex Ltd. has received a delisting notice from Nasdaq and plans to appeal the decision. Concurrently, the company announced a 1-for-16 reverse split of its ordinary shares, effective October 27, 2026. The appeal will temporarily stay any suspension or delisting action, allowing shares to continue trading on the Nasdaq Capital Market during this period.